Cited by

• Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.

  Corbett AH, Hosseinipour MC, Nyirenda J, Kanyama C, Rezk NL, Mkupani P, Sichali D, Tien H, Kashuba AD, Mwansambo C, Weigel R, Kazembe P. Corbett AH, et al. Antivir Ther. 2010;15(1):83-90. doi: 10.3851/IMP1488. Antivir Ther. 2010. PMID: 20167994 Free PMC article. Clinical Trial.
• Antiretroviral therapy supply chain quality control and assurance in improving people living with HIV therapeutic outcomes in Cameroon.

  Djobet MP, Singhe D, Lohoue J, Kuaban C, Ngogang J, Tambo E. Djobet MP, et al. AIDS Res Ther. 2017 Apr 4;14(1):19. doi: 10.1186/s12981-017-0147-x. AIDS Res Ther. 2017. PMID: 28376825 Free PMC article.
• Substandard/counterfeit antimicrobial drugs.

  Kelesidis T, Falagas ME. Kelesidis T, et al. Clin Microbiol Rev. 2015 Apr;28(2):443-64. doi: 10.1128/CMR.00072-14. Clin Microbiol Rev. 2015. PMID: 25788516 Free PMC article. Review.
• A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.

  von Hentig N, Carlebach A, Gute P, Knecht G, Klauke S, Rohrbacher M, Stocker H, Kurowski M, Harder S, Staszewski S, Haberl A. von Hentig N, et al. Br J Clin Pharmacol. 2006 Nov;62(5):552-9. doi: 10.1111/j.1365-2125.2006.02664.x. Br J Clin Pharmacol. 2006. PMID: 17061962 Free PMC article.
• Effectiveness of generic and proprietary first-line anti-retroviral regimens in a primary health care setting in Lusaka, Zambia: a cohort study.

  Stringer JS, Mwango AJ, Giganti MJ, Mulenga L, Levy JW, Stringer EM, Mulenga P, Saag MS, Musonda P, Williams FB, Reid SE, Chi BH. Stringer JS, et al. Int J Epidemiol. 2012 Apr;41(2):448-59. doi: 10.1093/ije/dys022. Int J Epidemiol. 2012. PMID: 22493326 Free PMC article.